Northwest Biotherapeutics | NWBO - Ebitda


Northwest Biotherapeutics reported $-13.41M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Celldex Therapeutics USD -72.79M 9.81M Sep/2025
Eisai JPY 30.1B 6.62B Dec/2025
Infinity Pharmaceuticals USD -10.01M 1.39M Jun/2023
Merck USD 8.39B 1.97B Sep/2025
Northwest Biotherapeutics USD -13.41M 232K Sep/2023
Pfizer USD 6.08B 351M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024